Page Banner

United States Department of Agriculture

Agricultural Research Service

Related Topics

Research Project: Effective Molecular Vaccines Against Foot and Mouth Disease

Location: Foreign Animal Disease Research

Project Number: 8064-32000-061-15-R
Project Type: Reimbursable Cooperative Agreement

Start Date: Aug 15, 2013
End Date: Dec 31, 2017

ARS, PIADC and the Indian Council of Agricultural Research institutes, Indian Veterinary Research Institute (IVRI) and the Project Directorate on Foot-and-Mouth Disease (PD FMD), are engaged in collaborative research to conduct antigenic and genetic characterization of FMD field virus isolates, surveillance, monitoring and vaccine strain selection for FMD control programs in India. This research project provides the additional capacity building support to develop the Human Defective Adenovirus Vector 5 vaccine, the optimization of the scaling procedures of these vaccines and the initial vaccination trials in India.

Indian Foot-and-Mouth Disease vaccine strains capsid sequences will be cloned and expressed in Human Defective Adenovirus Vector 5 (Ad5FMD) vector. Cattle will be immunized with these constructs of serotypes A, O and Asia1. Field strains genetically closest to vaccine strains but with different antigenic coverage (i.e. poor vaccine coverage) will be compared to the sequence of the corresponding vaccine strain. Specific divergent amino acids predicted to affect antigenic structure will be mutated on the vaccine strain and expressed in hAd5. The structural protein mutants will be transferred to the shuttle plasmid with all of them being individually introduced to the hAd5 backbone. Individual cloning and shuttle plasmids will be shipped out of the BSL-3 laboratory at PIADC and sent to IVRI for further development. Animals will be vaccinated and challenge with hAd5 vaccine strain or mutated vaccine strain and challenged with field strain in order to determine if the introduced mutations broadened the vaccine response and induced protection against heterologous challenge. This process will be carried out for serotype A initially.

Last Modified: 10/19/2017
Footer Content Back to Top of Page